{"id":41673,"date":"2025-09-17T13:57:22","date_gmt":"2025-09-17T05:57:22","guid":{"rendered":"https:\/\/flcube.com\/?p=41673"},"modified":"2025-09-17T13:57:23","modified_gmt":"2025-09-17T05:57:23","slug":"shanghai-henlius-biotech-negotiates-potential-sale-of-hlx43-adc-to-johnson-johnson-and-roche","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41673","title":{"rendered":"Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson\u202f&amp;\u202fJohnson and Roche"},"content":{"rendered":"\n<p><strong>Henlius Biotech Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) is reportedly in talks with global pharmaceutical giants <strong>Johnson\u202f&amp;\u202fJohnson<\/strong> (J&amp;J, <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE: JNJ<\/a>) and <strong>Roche<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ROG:SWX\">SWX: ROG<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>) to sell the rights to its experimental <strong>HLX43<\/strong> antibody\u2011drug conjugate (ADC), which targets the <strong>PD\u2011L1<\/strong> immune checkpoint. Bloomberg reports that the deal could bring the company a <strong>several\u2011hundred\u2011million\u2011dollar upfront payment<\/strong> plus additional milestone payouts, depending on future data releases.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Product<\/strong> \u2013 HLX43, a next\u2011generation ADC designed to inhibit PD\u2011L1, potentially enhancing antitumor immune responses.<\/li>\n\n\n\n<li><strong>Strategic Buyers<\/strong> \u2013 Johnson\u202f&amp;\u202fJohnson and Roche, both heavy\u2011weights in oncology therapeutics, seeking to expand their ADC pipelines.<\/li>\n\n\n\n<li><strong>Financial Upside<\/strong> \u2013 Initial payment projected in the <strong>hundreds of millions<\/strong>, with further milestone payments contingent on preclinical and early\u2011phase clinical success.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-negotiation-dynamics\">Negotiation Dynamics<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Data\u2011Driven Valuation<\/strong> \u2013 Henlius may push for higher terms as additional efficacy and safety data emerge.<\/li>\n\n\n\n<li><strong>Uncertain Outcome<\/strong> \u2013 No definitive agreement has been reached; the parties are still negotiating terms and milestones.<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong> \u2013 The ADC market is rapidly evolving, with multiple players vying for the PD\u2011L1 niche.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-company-context\">Company Context<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Henlius Biotech<\/strong> \u2013 A Shanghai\u2011based biotech focused on antibody\u2011drug conjugates and other precision oncology modalities.<\/li>\n\n\n\n<li><strong>Pipeline<\/strong> \u2013 HLX43 is currently in the preclinical phase, with promising in\u2011vitro results against PD\u2011L1\u2011expressing tumor models.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic Fit<\/strong> \u2013 Acquiring HLX43 would bolster Johnson\u202f&amp;\u202fJohnson\u2019s and Roche\u2019s ADC arsenals, potentially accelerating their entry into PD\u2011L1\u2011targeted therapies.<\/li>\n\n\n\n<li><strong>Investor Sentiment<\/strong> \u2013 A successful transaction could enhance Henlius\u2019s valuation and provide capital to advance other pipeline assets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Henlius Biotech Inc. (HKG: 2696) is reportedly in talks with global pharmaceutical giants Johnson\u202f&amp;\u202fJohnson (J&amp;J,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41674,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[35,862,150,149,858,940,18,163,939],"class_list":["post-41673","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-adc-xdc","tag-hkg-2696","tag-jj","tag-johnson-johnson","tag-nyse-jnj","tag-otcmkts-rhhby","tag-pd-1-l1","tag-roche","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson\u202f&amp;\u202fJohnson and Roche - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Henlius Biotech Inc. (HKG: 2696) is reportedly in talks with global pharmaceutical giants Johnson\u202f&amp;\u202fJohnson (J&amp;J, NYSE: JNJ) and Roche (SWX: ROG, OTCMKTS: RHHBY) to sell the rights to its experimental HLX43 antibody\u2011drug conjugate (ADC), which targets the PD\u2011L1 immune checkpoint. Bloomberg reports that the deal could bring the company a several\u2011hundred\u2011million\u2011dollar upfront payment plus additional milestone payouts, depending on future data releases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41673\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson\u202f&amp;\u202fJohnson and Roche\" \/>\n<meta property=\"og:description\" content=\"Henlius Biotech Inc. (HKG: 2696) is reportedly in talks with global pharmaceutical giants Johnson\u202f&amp;\u202fJohnson (J&amp;J, NYSE: JNJ) and Roche (SWX: ROG, OTCMKTS: RHHBY) to sell the rights to its experimental HLX43 antibody\u2011drug conjugate (ADC), which targets the PD\u2011L1 immune checkpoint. Bloomberg reports that the deal could bring the company a several\u2011hundred\u2011million\u2011dollar upfront payment plus additional milestone payouts, depending on future data releases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41673\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-17T05:57:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-17T05:57:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1703.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41673#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41673\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson\u202f&amp;\u202fJohnson and Roche\",\"datePublished\":\"2025-09-17T05:57:22+00:00\",\"dateModified\":\"2025-09-17T05:57:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41673\"},\"wordCount\":280,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41673#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1703.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"HKG: 2696\",\"J&amp;J\",\"Johnson &amp; Johnson\",\"NYSE: JNJ\",\"OTCMKTS: RHHBY\",\"PD-1\\\/L1\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41673#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41673\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41673\",\"name\":\"Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson\u202f&amp;\u202fJohnson and Roche - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41673#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41673#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1703.webp\",\"datePublished\":\"2025-09-17T05:57:22+00:00\",\"dateModified\":\"2025-09-17T05:57:23+00:00\",\"description\":\"Henlius Biotech Inc. (HKG: 2696) is reportedly in talks with global pharmaceutical giants Johnson\u202f&\u202fJohnson (J&J, NYSE: JNJ) and Roche (SWX: ROG, OTCMKTS: RHHBY) to sell the rights to its experimental HLX43 antibody\u2011drug conjugate (ADC), which targets the PD\u2011L1 immune checkpoint. Bloomberg reports that the deal could bring the company a several\u2011hundred\u2011million\u2011dollar upfront payment plus additional milestone payouts, depending on future data releases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41673#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41673\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41673#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1703.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1703.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson\u202f&\u202fJohnson and Roche\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41673#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson\u202f&amp;\u202fJohnson and Roche\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson\u202f&amp;\u202fJohnson and Roche - Insight, China&#039;s Pharmaceutical Industry","description":"Henlius Biotech Inc. (HKG: 2696) is reportedly in talks with global pharmaceutical giants Johnson\u202f&\u202fJohnson (J&J, NYSE: JNJ) and Roche (SWX: ROG, OTCMKTS: RHHBY) to sell the rights to its experimental HLX43 antibody\u2011drug conjugate (ADC), which targets the PD\u2011L1 immune checkpoint. Bloomberg reports that the deal could bring the company a several\u2011hundred\u2011million\u2011dollar upfront payment plus additional milestone payouts, depending on future data releases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41673","og_locale":"en_US","og_type":"article","og_title":"Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson\u202f&amp;\u202fJohnson and Roche","og_description":"Henlius Biotech Inc. (HKG: 2696) is reportedly in talks with global pharmaceutical giants Johnson\u202f&\u202fJohnson (J&J, NYSE: JNJ) and Roche (SWX: ROG, OTCMKTS: RHHBY) to sell the rights to its experimental HLX43 antibody\u2011drug conjugate (ADC), which targets the PD\u2011L1 immune checkpoint. Bloomberg reports that the deal could bring the company a several\u2011hundred\u2011million\u2011dollar upfront payment plus additional milestone payouts, depending on future data releases.","og_url":"https:\/\/flcube.com\/?p=41673","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-17T05:57:22+00:00","article_modified_time":"2025-09-17T05:57:23+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1703.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41673#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41673"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson\u202f&amp;\u202fJohnson and Roche","datePublished":"2025-09-17T05:57:22+00:00","dateModified":"2025-09-17T05:57:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41673"},"wordCount":280,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41673#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1703.webp","keywords":["ADC \/ XDC","HKG: 2696","J&amp;J","Johnson &amp; Johnson","NYSE: JNJ","OTCMKTS: RHHBY","PD-1\/L1","Roche","SWX: ROP"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41673#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41673","url":"https:\/\/flcube.com\/?p=41673","name":"Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson\u202f&amp;\u202fJohnson and Roche - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41673#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41673#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1703.webp","datePublished":"2025-09-17T05:57:22+00:00","dateModified":"2025-09-17T05:57:23+00:00","description":"Henlius Biotech Inc. (HKG: 2696) is reportedly in talks with global pharmaceutical giants Johnson\u202f&\u202fJohnson (J&J, NYSE: JNJ) and Roche (SWX: ROG, OTCMKTS: RHHBY) to sell the rights to its experimental HLX43 antibody\u2011drug conjugate (ADC), which targets the PD\u2011L1 immune checkpoint. Bloomberg reports that the deal could bring the company a several\u2011hundred\u2011million\u2011dollar upfront payment plus additional milestone payouts, depending on future data releases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41673#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41673"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41673#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1703.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1703.webp","width":1080,"height":608,"caption":"Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson\u202f&\u202fJohnson and Roche"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41673#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson\u202f&amp;\u202fJohnson and Roche"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1703.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41673"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41673\/revisions"}],"predecessor-version":[{"id":41675,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41673\/revisions\/41675"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41674"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}